Date: 2015-11-10
Type of information: Nomination
Compound:
Company: AmpliPhi BioSciences (USA - VA)
Therapeutic area: Infectious diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On November 10, 2015, AmpliPhi Biosciences, a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, announced that Vijay B. Samant and Paul C. Grint, M.D. have been appointed to its Board of Directors as Non-Executive Directors. As current CEOs of NASDAQ listed companies, Mr. Samant and Dr. Grint both have significant experience serving on the boards of publicly-listed companies, and also enhance AmpliPhi’s commercial leadership experience as it matures towards a clinical stage company. Mr. Samant is President and CEO of Vical, Inc., a developer of biopharmaceutical products for the prevention and treatment of chronic life-threatening infectious diseases. Prior to Vical, Mr Samant gained over two decades of U.S. and international sales, marketing, operations and business development experience at Merck & Co, serving as CEO of the Merck Vaccine Division, VP of Vaccine Operations, VP of Business Affairs and Executive Director of Materials Management. Mr. Samant has served on the boards of Raptor Pharmaceuticals, BioMarin, Aeras Global TB Vaccine Foundation, The National Foundation for Infectious Diseases and the International Vaccine Institute. He holds a bachelor’s degree in chemical engineering from the University of Bombay, a master’s degree in chemical engineering from Columbia University and a master’s in management studies from the Sloan School of Management at the Massachusetts Institute of Technology. Dr. Grint is President and CEO of Regulus Therapeutics, Inc., a company focused on the discovery and development of microRNA therapeutics. Dr. Grint has over two decades of experience in biologics and small molecule development, including the successful commercialization of products in oncology, anti-infectives and immunology. Prior to his role at Regulus, he served as President of Cerexa, Inc. Dr. Grint has also served in senior management roles at Forest Research Institute, Kalypsys, Zephyr Sciences, Pfizer, IDEC Pharmaceuticals and Schering-Plough Corporation. He is a Fellow of the Royal College of Pathologists, and is a member of numerous professional and medical societies. He holds a degree from St. Mary’s College, University of London and a medical degree from St. Bartholomew’s Hospital College, University of London.
Financial terms:
Latest news:
